Patients with previously treated metastatic pancreatic cancer are receiving an investigational drug that has not yet been approved, through a federal pathway that opened this spring.
The drug is daraxonrasib, an oral RAS inhibitor developed by Revolution Medicines. In the Phase 3 RASolute 302 trial, patients receiving it had a median overall survival of 13.2 months in the overall study population, compared with 6.7 months for those receiving standard chemotherapy, a 60 percent reduction in the risk of death.
A common assumption about the drug is worth correcting immediately, because it determines who can ask about it. The trial enrolled patients with previously treated metastatic pancreatic ductal adenocarcinoma with or without an identified tumor RAS mutation, and the expanded access protocol is open regardless of mutation status. Genetic testing is not the gate for this particular drug.
Expanded Access Is Not Approval
The distinction between these two things is the single most consequential detail for a family trying to navigate this.
The FDA issued a safe-to-proceed letter allowing Revolution Medicines to open an expanded access treatment protocol, granting the request two days after receiving it. The company submitted the application on April 28, and the agency signed off on April 30, a turnaround the FDA cited as reflecting its commitment to early access for serious conditions.
Expanded access, sometimes called compassionate use, lets patients receive an investigational drug outside a clinical trial when other options are limited. It is not an approval and does not mean the drug has been found safe and effective by the agency.
The application route runs through the physician, not the patient. A U.S. licensed physician must submit the request to the manufacturer on an eligible patient's behalf, and local institutional review board approval is also required. Eligibility is limited to adults with previously treated metastatic pancreatic cancer who have no comparable or satisfactory alternative and who cannot participate in an ongoing trial.
Separately, the FDA accepted the company's new drug application for review on July 22 under the Commissioner's National Priority Voucher pilot program, under which review time is anticipated to be one to two months rather than the usual ten to twelve. Daraxonrasib had previously received Breakthrough Therapy and Orphan Drug designations, and European regulators have begun a phased review.
The Trial Did Not Require a Mutation
RAS mutations are present in more than 90 percent of pancreatic adenocarcinoma cases, which is part of why a multi-selective RAS inhibitor was pursued in this disease.
Daraxonrasib is described as a RAS(ON) multi-selective inhibitor, meaning it targets the active form of the protein across multiple variants rather than one specific mutation. That design is why the registrational trial did not restrict enrollment by mutation status, and it separates this drug from single-mutation targeted therapies where a specific test result determines eligibility.
One nuance matters for reading the results. The trial's dual primary endpoints, overall survival and progression-free survival, were assessed in the RAS G12-mutant population, where median overall survival was 13.2 months versus 6.6 months with chemotherapy. Patients with RAS wild-type disease were also enrolled, and the overall population result was 13.2 months versus 6.7 months.
Other measures moved in the same direction. Median progression-free survival was 7.3 months with daraxonrasib versus 3.5 months with chemotherapy, and the 12-month survival rate was 53.3 percent versus 18.7 percent.
Dr. Brian Wolpin of Dana-Farber Cancer Institute, the trial's principal investigator, presented the full analysis in a plenary session at the 2026 American Society of Clinical Oncology annual meeting, with simultaneous publication in The New England Journal of Medicine. The presentation drew a standing ovation, an unusual response in a disease where trials have repeatedly failed.
Enthusiasm is not the same as a settled answer. The trial establishes a survival benefit in the second-line setting, in patients who had progressed on one prior regimen. It does not establish that the drug works in earlier lines, and additional Phase 3 trials are still enrolling in the first-line metastatic and other settings.
Molecular Profiling Still Matters Here
None of the above means genetic testing is irrelevant in pancreatic cancer. It means it is relevant for different reasons than many people assume.
Comprehensive molecular profiling of pancreatic tumors can identify findings that open other treatment doors: BRCA1 or BRCA2 alterations that may indicate benefit from certain maintenance therapy, mismatch repair deficiency or high microsatellite instability that can indicate immunotherapy eligibility, NTRK fusions, and specific KRAS variants relevant to other agents in development. Germline testing is recommended for people diagnosed with pancreatic cancer regardless of family history, because results carry implications for relatives.
Many patients never receive this testing. Tissue can be limited from a biopsy of a small tumor, results take time that advanced patients may not have, and insurance coverage varies. Those are the real barriers, and they are logistical more often than clinical.
Patients or families can ask the oncology team directly whether comprehensive genomic profiling has been ordered, whether tissue- or blood-based testing is being used, and whether germline testing has been discussed. If profiling has not been done, asking why is reasonable.
Steps for Patients and Families Asking About Access
Start with the treating oncologist. Only a physician can request expanded access, and the request goes to the manufacturer rather than to the FDA.
Ask specifically whether the patient meets the protocol criteria, whether the treating institution's review board can process the request, and what the expected timeline is. Expanded access involves administrative work, review approvals, and reporting requirements that community practices may not routinely handle.
Ask about clinical trials in parallel. Trial participation is generally preferred where a suitable trial is open, and expanded access is designed for people who cannot enroll.
Patients should not attempt to obtain investigational drugs through any channel other than a physician and the manufacturer. Products sold online claiming to be investigational cancer drugs are not the drug being studied.
Anyone with pancreatic cancer experiencing new severe abdominal or back pain, jaundice, uncontrolled vomiting, fever, or sudden confusion should seek prompt medical evaluation rather than waiting for a scheduled appointment.
A regulatory decision could come quickly given the accelerated review pathway. MedicalDaily will report the outcome and any change to access pathways.
Key Questions Answered
Is daraxonrasib FDA-approved? No. It is available through an expanded access treatment protocol while a new drug application is under review.
Does a patient need a specific genetic mutation to qualify? No. The pivotal trial enrolled patients with or without an identified tumor RAS mutation, and expanded access is open regardless of status.
How does someone get the drug? A U.S. licensed physician must submit a request to the manufacturer on the patient's behalf, with institutional review board approval.
Who is eligible? Adults with previously treated metastatic pancreatic cancer who have no comparable alternative and cannot join an ongoing trial.
What did the trial show? Median overall survival of 13.2 months versus 6.7 months with chemotherapy in the overall population, and 13.2 versus 6.6 months in the RAS G12-mutant group.
Is genetic testing still worth doing? Yes, for other reasons. Profiling can identify BRCA alterations, mismatch repair deficiency, NTRK fusions, and other findings affecting treatment options.
When could approval come? The FDA accepted the application in July under a pilot program where review is anticipated to take one to two months.
